TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12564654

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) 12 microg taken twice daily
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) 24 microg taken twice daily
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) used as regular maintenance treatment and rescue medication
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) total daily dose of 48 microg or less
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (Foradil) regimen
Number of subjects: 500
Study: 10214889

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (AZ) 2 mg + S-carboxymethyl cysteine (SCMC) 750 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: S-carboxymethyl cysteine (SCMC) 750 mg
Number of subjects: 53
Study: 7611378

Group type: EXPERIMENTAL
Intervention: 1 mg/day digoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2171792

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 60
Study: 432544

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass (3:1 ratio)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass (1:3 ratio)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unoperated
Number of subjects: 24
Study: 31773810

Group type: EXPERIMENTAL
Intervention: Unassisted Netra
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Refined Netra
Number of subjects: 36

Group type: COMPARATOR
Intervention: Professional subjective refraction
Number of subjects: 36
Study: 30702997

Group type: EXPERIMENTAL
Intervention: Dual pathway inhibition with low-dose rivaroxaban (2.5 mg twice-daily) plus acetylsalicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid alone
Number of subjects: 0
Study: 29801012

Group type: EXPERIMENTAL
Intervention: Hydration group (coached to drink more water)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Hydration group
Number of subjects: 631

Group type: COMPARATOR
Intervention: Control group (coached to maintain usual intake)
Number of subjects: 631
Study: 26717035

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus (EVR + Reduced TAC)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Conventional tacrolimus-based therapy (TAC Control)
Number of subjects: 719
Study: 24374721

Group type: EXPERIMENTAL
Intervention: Stigma-reduction intervention involving training of 30 popular opinion leaders in each intervention hospital to disseminate stigma-reduction messages.
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Stigma-reduction intervention
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Control condition (matched hospitals without the intervention)
Number of subjects: 1760
Study: 21870979

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1 g twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study: 20584997

Group type: EXPERIMENTAL
Intervention: Public insurance
Number of subjects: 776

Group type: COMPARATOR
Intervention: Uninsured
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Overall (all insurance statuses)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Insurance status
Number of subjects: 776
Study: 17554878

Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium gluconate
Number of subjects: 40
Study: 16254224

Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz, 25 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 11903066

Group type: EXPERIMENTAL
Intervention: Cold cardiopulmonary bypass with alpha-stat
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cold cardiopulmonary bypass with pH-stat
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass with alpha-stat
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass with pH-stat
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cold cardiopulmonary bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass
Number of subjects: 60
Study: 10065662

Group type: EXPERIMENTAL
Intervention: 25 mg patch for 22 weeks (L-25)
Number of subjects: 3575

Group type: EXPERIMENTAL
Intervention: 25 mg patch for 8 weeks (S-25)
Number of subjects: 3575

Group type: EXPERIMENTAL
Intervention: 15 mg patch for 22 weeks (L-15)
Number of subjects: 3575

Group type: EXPERIMENTAL
Intervention: 15 mg patch for 8 weeks (S-15)
Number of subjects: 3575

Group type: COMPARATOR
Intervention: Placebo (P-0)
Number of subjects: 3575
Study: 7488408

Group type: EXPERIMENTAL
Intervention: Postoperative platinum-based chemotherapy (two cycles)
Number of subjects: 174

Group type: COMPARATOR
Intervention: RPLND alone
Number of subjects: 174

Group type: COMPARATOR
Intervention: Pathological stage A
Number of subjects: 174
Study: 1962154

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound treatment (1 MHz; 1:4; 1 W/cm2, 10 min/session, 2-3 times weekly for 10 treatments)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study: 6127896

Group type: EXPERIMENTAL
Intervention: Prenalterol 12.5, 25, and 50 micrograms
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prenalterol after hydralazine and isosorbide dinitrate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 18
Study: 31629646

Group type: EXPERIMENTAL
Intervention: Supported Discharge Team (SDT)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 403
Study: 31092165

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study: 29117413

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted clear corneal incision (LENSAR, Inc., Orlando, FL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Manual clear corneal incision (with a 2.4-mm keratome)
Number of subjects: 62
Study: 26071040

Group type: EXPERIMENTAL
Intervention: TXA 1 g
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study: 23873583

Group type: EXPERIMENTAL
Intervention: Double therapy (peginterferon α‐2b and ribavirin for 20 weeks)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Triple therapy (peginterferon α‐2b, ribavirin, and boceprevir for 24 weeks)
Number of subjects: 233
Study: 22313979

Group type: EXPERIMENTAL
Intervention: Xeno IV
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Prompt‐L‐Pop
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AdheSE One
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bond Force
Number of subjects: 90

Group type: COMPARATOR
Intervention: Optibond
Number of subjects: 90
Study: 20571786

Group type: EXPERIMENTAL
Intervention: teriparatide treatment (20 microg/day)
Number of subjects: 44
Study: 17643390

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 52
Study: 15651569

Group type: EXPERIMENTAL
Intervention: New procedure for measuring fluorescein leakage using confocal scanning laser ophthalmoscope (CSLO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing methods for assessment of fluorescein leakage (qualitative evaluation of fluorescein angiographies and volume measurements by Fluorotron Master)
Number of subjects: 0
Study: 12383454

Group type: EXPERIMENTAL
Intervention: Earlier first intercourse
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 79
Study: 10024114

Group type: EXPERIMENTAL
Intervention: hGH (12 IU/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7594255

Group type: EXPERIMENTAL
Intervention: Dayroom program focused on functional needs
Number of subjects: 0
Study: 2261895

Group type: EXPERIMENTAL
Intervention: Soy based formula
Number of subjects: 21

Group type: COMPARATOR
Intervention: Full cream cows' milk or low lactose formula
Number of subjects: 21
Study: 6805002

Group type: EXPERIMENTAL
Intervention: Pimozide (10-70 mg/day, median 30 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorpromazine (600-1500 mg/day, median 900 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pimozide and Chlorpromazine
Number of subjects: 40
Study: 31350391

Group type: EXPERIMENTAL
Intervention: FluBlok
Number of subjects: 0

Group type: COMPARATOR
Intervention: FluCelvax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluzone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat vaccinations (all platforms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior year vaccination
Number of subjects: 0
Study: 28727908

Group type: EXPERIMENTAL
Intervention: MK-8666 500 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MK-8666 150 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MK-8666 50 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 26348088

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT) treatment, maximum dose 200 mg/day, over 72-300 days (mean=164.2, SD=68.3).
Number of subjects: 11
Study: 23566419

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg) twice daily for two to three weeks (n = 22)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Celecoxib vs Placebo
Number of subjects: 37
Study: 22060250

Group type: EXPERIMENTAL
Intervention: Attentional Modification Paradigm (AMP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 17
Study: 19549430

Group type: EXPERIMENTAL
Intervention: Mometasone 400 micrograms once daily for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17720853

Group type: EXPERIMENTAL
Intervention: 0.1% hop bract polyphenols (HBP) mouthrinse
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 29
Study: 16702870

Group type: EXPERIMENTAL
Intervention: 1.0% carboxymethylcellulose (CMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: propylene glycol/polyethylene glycol 400 (PG‐HPG)
Number of subjects: 0
Study: 15143476

Group type: EXPERIMENTAL
Intervention: 11PncTD1 (1 dose of adjuvanted, 11-valent pneumococcal conjugate vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 11PncTD3 (3 doses of adjuvanted, 11-valent pneumococcal conjugate vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both 11PncTD1 and 11PncTD3
Number of subjects: 0
Study: 10748306

Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Brachial artery diameter
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brachial artery diameter change
Number of subjects: 26
Study: 8729585

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg and 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0
Study: 1568660

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 12 mg/kg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA, 12 mg/kg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bedtime administration of UDCA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mealtime administration of UDCA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination therapy (CDCA 6 mg/kg/day + UDCA 6 mg/kg/day at bedtime)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CDCA alone
Number of subjects: 48
Study: 2866777

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2 mg flunitrazepam
Number of subjects: 32
Study: 31780130

Group type: EXPERIMENTAL
Intervention: iCBT (internet-delivered cognitive behavioural therapy)
Number of subjects: 391
Study: 30526264

Group type: EXPERIMENTAL
Intervention: Scopolamine patch
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 33
Study: 28249134

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1203
Study: 24706493

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 to 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-escalators
Number of subjects: 0
Study: 24253810

Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide followed by docetaxel + bevacizumab
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Docetaxel + doxorubicin + cyclophosphamide + bevacizumab
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Docetaxel + carboplatin + trastuzumab + bevacizumab
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: All arms received bevacizumab
Number of subjects: 212
Study: 22120090

Group type: COMPARATOR
Intervention: Tolvaptan 15-120 mg single dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tolvaptan 30-120 mg once daily for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tolvaptan 60 mg and above
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tolvaptan
Number of subjects: 100
Study: 19101459

Group type: COMPARATOR
Intervention: Condoms only
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: No effective method
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: OC only
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: Dual OC and condoms
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: Emergency contraception
Number of subjects: 1952
Study: 18219850

Group type: COMPARATOR
Intervention: Trastuzumab alone therapy (A-group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus taxane therapy (B-group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus taxane therapy (after addition to A-group)
Number of subjects: 18
Study: 14976789

Group type: EXPERIMENTAL
Intervention: Surgical team changed gloves after delivery of the placenta
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (surgical gloves not changed)
Number of subjects: 92
Study: 11310943

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 6921

Group type: EXPERIMENTAL
Intervention: SF-36 components
Number of subjects: 6921
Study: 9333181

Group type: COMPARATOR
Intervention: Sb alone for 30 days (group A)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Sb plus IFN‐gamma for 30 days (group B)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Sb plus IFN‐gamma for 15 days (group C)
Number of subjects: 156
Study: 7631088

Group type: EXPERIMENTAL
Intervention: VPL pallidotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right-sided VPL thalamotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventrolateral thalamotomy
Number of subjects: 0
Study: 3605748

Group type: EXPERIMENTAL
Intervention: Thiopental treatment (EEG suppression)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isoflurane treatment (EEG suppression)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no further anesthetics during bypass and continuous EEG activity)
Number of subjects: 31
Study: 29952443

Group type: EXPERIMENTAL
Intervention: DVD inhaler instruction
Number of subjects: 21

Group type: COMPARATOR
Intervention: Individual education with a physiotherapist
Number of subjects: 21
Study: 28672405

Group type: EXPERIMENTAL
Intervention: Long-term antidepressant treatment (SSRI/SNRI) for 6-52 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No antidepressant treatment (with or without benzodiazepine medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 25537835

Group type: EXPERIMENTAL
Intervention: Diluted insulin aspart (20 U/ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard insulin aspart (100 U/ml)
Number of subjects: 11
Study: 23866779

Group type: EXPERIMENTAL
Intervention: Sinus membrane elevation without bone grafting
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sinus membrane elevation with bone grafting
Number of subjects: 14
Study: 21943105

Group type: EXPERIMENTAL
Intervention: Needling at BL33
Number of subjects: 100

Group type: COMPARATOR
Intervention: Needling at non-point (control)
Number of subjects: 100
Study: 18279058

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX-4
Number of subjects: 2000

Group type: COMPARATOR
Intervention: FOLFOX-4 alone
Number of subjects: 2000
Study: 16780768

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Direct Laryngoscope (DLS)
Number of subjects: 53
Study: 15181098

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 31
Study: 10799353

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8957583

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 133
Study: 1416131

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 32
Study: 2987133

Group type: EXPERIMENTAL
Intervention: Sulbactam-ampicillin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 103
Study: 29325171

Group type: EXPERIMENTAL
Intervention: Maternal and Child Health Handbook (MCHHB) provision at antenatal care visits; records and guides by health personnel; sensitization of care by volunteers
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Maternal and Child Health Handbook (MCHHB) use
Number of subjects: 454
Study: 29058084

Group type: EXPERIMENTAL
Intervention: CAF + PRF
Number of subjects: 24

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 24
Study: 27354224

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: LVEF < 15%
Number of subjects: 2305
Study: 24786613

Group type: EXPERIMENTAL
Intervention: POBC‐URSL
Number of subjects: 156
Study: 22084206

Group type: EXPERIMENTAL
Intervention: Dual-energy CTPA (image reconstruction at 50 keV) with 50% reduction in iodine load (n = 48)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard CTPA (100-120 kVp) with standard contrast medium injection (n = 46)
Number of subjects: 94
Study: 20815182

Group type: EXPERIMENTAL
Intervention: Recovery sleep doses of 0, 2, 4, 6, 8, or 10 h TIB after 5 nights of sleep restriction to 4 h TIB
Number of subjects: 159

Group type: COMPARATOR
Intervention: 10 h TIB on all nights (control condition)
Number of subjects: 159
Study: 19083445

Group type: EXPERIMENTAL
Intervention: BTE tablets (333 mg)
Number of subjects: 47
Study: 16817011

Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12785023

Group type: EXPERIMENTAL
Intervention: Surgery (ligation) followed by sclerotherapy (Group F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foam-sclerotherapy (Group E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sclerotherapy (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose sclerotherapy (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple ligations (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stab avulsion (Group D)
Number of subjects: 0
Study: 10716475

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Ang II type 1 receptor antagonist)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9207725

Group type: EXPERIMENTAL
Intervention: Bevel-down method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bevel-up method
Number of subjects: 10
Study: 8280514

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of left ventricular function during exercise using a miniature nuclear probe (Cardioscint)
Number of subjects: 31
Study: 3510333

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 82
Study: 31327040

Group type: EXPERIMENTAL
Intervention: Right access for PTBD (group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Left access for PTBD (group B)
Number of subjects: 64
Study: 29525929

Group type: EXPERIMENTAL
Intervention: Perceived need for treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family factors (low cohesion and high conflict)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical factors (adolescent internalizing and externalizing symptomatology)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical and family factors
Number of subjects: 0
Study: 26603892

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 24514907

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training with 250 mg resveratrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-intensity exercise training with placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resveratrol (250 mg)
Number of subjects: 0
Study: 22395588

Group type: EXPERIMENTAL
Intervention: 5% dexpanthenol (DT) ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% hydrocortisone (HC) ointment
Number of subjects: 30
Study: 20808314

Group type: EXPERIMENTAL
Intervention: Siltuximab 3 mg/kg, q3w × 4
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Siltuximab 6 mg/kg, q3w × 4
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Siltuximab 6 mg/kg, q2w × 6
Number of subjects: 68
Study: 19025059

Group type: EXPERIMENTAL
Intervention: Estalin 2 mg tablets (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 mg tablets of the originator product (reference formulation)
Number of subjects: 24